Enhanced Anti-cancer Potency Using a Combination of Oleanolic Acid and Maslinic Acid to Control Treatment Resistance in Breast Cancer

被引:3
|
作者
Avci, Cigir Biray [1 ]
Sogutlu, Fatma [1 ]
Ozates, Neslihan Pinar [1 ]
Shademan, Behrouz [1 ]
Gunduz, Cumhur [1 ]
机构
[1] Ege Univ, Fac Med, Dept Med Biol, Izmir, Turkiye
关键词
Breast cancer mTOR signal; pathway Therapeutic resistance; Oleanolic acid Maslinic acid; CELL-CYCLE; APOPTOSIS; AUTOPHAGY; SURVIVAL; PATHWAY; GROWTH; AKT;
D O I
10.34172/apb.2023.057
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/ mTOR) pathway is a complex intracellular metabolic pathway that leads to cell growth and tumor proliferation and plays a key role in drug resistance in breast cancer. Therefore, the anti-cancer effects of oleanolic acid (OA), maslinic acid (MA), and their combination were investigated to improve the performance of the treatment strategy. Methods: We investigated the effect of OA and MA on cell viability using the WST-1 method. The synergistic effect of the combination was analyzed by isobologram analysis. In addition, the effects of the two compounds, individually and in combination, on apoptosis, autophagy, and the cell cycle were investigated in MCF7 cells. In addition, changes in the expression of PI3K/AKT/mTOR genes involved in apoptosis, cell cycle and metabolism were determined by quantitative RT-PCR. Results: MA, OA, and a combination of both caused G0/G1 arrest. Apoptosis also increased in all treated groups. The autophagosomal LC3-II formation was induced 1.74-fold in the MA -treated group and 3.25-fold in the MA-OA-treated group. The combination treatment resulted in increased expression of genes such as GSK3B, PTEN, CDKN1B and FOXO3 and decreased expression of IGF1, PRKCB and AKT3 genes. Conclusion: The results showed that the combination of these two substances showed the highest synergistic effect at the lowest dose and using MA-OA caused cancer cells to undergo apoptosis. The use of combination drugs may reduce the resistance of cancer cells to treatment.
引用
收藏
页码:611 / 620
页数:10
相关论文
共 50 条
  • [21] Anti-cancer Substances and Safety of Lactic Acid Bacteria in Clinical Treatment
    Liu, Chaoran
    Zheng, Jiaqi
    Ou, Xuan
    Han, Yuzhu
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [22] INDOLE-3-CARBOXYLIC ACID ENHANCED ANTI-CANCER POTENCY OF DOXORUBICIN VIA INDUCTION OF CELLULAR SENESCENCE IN COLORECTAL CELLS
    Zhou, Yao
    Tang, Yi
    Luo, Qingping
    Wu, Yuhang
    Peng, Wei
    ACTA POLONIAE PHARMACEUTICA, 2024, 81 (01): : 109 - 121
  • [23] Gallic Acid: A Potential Anti-Cancer Agent
    Jiang, Yuan
    Pei, Jin
    Zheng, Yan
    Miao, Yu-jing
    Duan, Bao-zhong
    Huang, Lin-fang
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2022, 28 (07) : 661 - 671
  • [24] Gallic Acid: A Potential Anti-Cancer Agent
    JIANG Yuan
    PEI Jin
    ZHENG Yan
    MIAO Yu-jing
    DUAN Bao-zhong
    HUANG Lin-fang
    Chinese Journal of Integrative Medicine, 2022, 28 (07) : 661 - 671
  • [25] Gallic Acid: A Potential Anti-Cancer Agent
    Yuan Jiang
    Jin Pei
    Yan Zheng
    Yu-jing Miao
    Bao-zhong Duan
    Lin-fang Huang
    Chinese Journal of Integrative Medicine, 2022, 28 : 661 - 671
  • [26] Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells
    Wu, Guo-Sheng
    Lu, Jin-Jian
    Guo, Jia-Jie
    Huang, Ming-Qing
    Gan, Li
    Chen, Xiu-Ping
    Wang, Yi-Tao
    PHARMACOLOGICAL REPORTS, 2013, 65 (02) : 453 - 459
  • [27] Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells
    Guo-Sheng Wu
    Jin-Jian Lu
    Jia-Jie Guo
    Ming-Qing Huang
    Li Gan
    Xiu-Ping Chen
    Yi-Tao Wang
    Pharmacological Reports, 2013, 65 : 453 - 459
  • [28] Clinical proteomics of response to anti-cancer treatment reveals metabolic control of treatment resistance
    Shenoy, Anjana
    Harel, Michal
    Dadiani, Maya
    Barshack, Iris
    Kaufmann, Bella
    Markel, Gal
    Geiger, Tamar
    MOLECULAR & CELLULAR PROTEOMICS, 2017, 16 (08) : S67 - S67
  • [29] Combination of multifunctional ursolic acid with kinase inhibitors for anti-cancer drug carrier vesicles
    Lorincz, A.
    Mihaly, J.
    Wacha, A.
    Nemeth, Cs.
    Besztercei, B.
    Gyulavari, P.
    Varga, Z.
    Petak, I.
    Bota, A.
    MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2021, 131
  • [30] Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer
    Oliveras, G.
    Blancafort, A.
    Urruticoechea, A.
    Campuzano, O.
    Gomez-Cabello, D.
    Brugada, R.
    Lopez-Rodriguez, M. L.
    Colomer, R.
    Puig, T.
    TOWARD PERSONALIZED MEDICINE FOR CANCER, 2010, 1210 : 86 - 93